/C O R R E C T I O N -- Cellipont Bioservices/
Rhea-AI Summary
Cellipont Bioservices and Ernexa Therapeutics (ERNA) announced a manufacturing collaboration on Oct. 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, toward clinical manufacturing and trials. The agreement covers engineering, differentiation, and production (EDP) activities and cGMP development and scale-up of the ERNA-101 process. ERNA-101 has shown preclinical potential to convert immunologically "cold" tumors into "hot" tumors, with data presented at AACR and ASCO. No financial terms or clinical timelines were disclosed.
Positive
- cGMP development and scale-up for ERNA-101 manufacturing
- Partnership targets clinical manufacturing to enable trials
- Allogeneic iMSC approach offers off-the-shelf scalability
Negative
- No financial terms, timelines, or binding trial start dates disclosed
- ERNA-101 efficacy limited to preclinical data so far
News Market Reaction 20 Alerts
On the day this news was published, ERNA gained 40.80%, reflecting a significant positive market reaction. Argus tracked a peak move of +102.3% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $20M at that time. Trading volume was exceptionally heavy at 4144.6x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
In the news release, Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer, issued Oct. 29, 2025 by Cellipont Bioservices over PR Newswire, we are advised by the company that the logo has been updated. The complete press release that includes the updated logo follows:
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
"We are pleased to collaborate with Ernexa Therapeutics as they advance a bold and highly differentiated approach to treating cancer," said Darren Head, CEO of Cellipont Bioservices. "Supporting the development of synthetic, allogeneic iMSC therapies like ERNA-101 aligns with our commitment to enabling scientific innovation through collaborative, high-quality cell therapy manufacturing."
"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy," said Sanjeev Luther, President and CEO of Ernexa Therapeutics. "This collaboration marks an important milestone in advancing our iMSC platform, which we believe has the potential to reshape the treatment landscape for patients with advanced solid tumors."
Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). iMSC is a more specialized type of stem cell that has a unique ability to migrate toward tumors. Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting. ERNA-101 is Ernexa's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells.
In preclinical studies, presented at this year's AACR and ASCO annual meetings, ERNA-101 has shown the potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth. The Cellipont partnership will support the current Good Manufacturing Practice (cGMP) development and scale-up of the ERNA-101 manufacturing process in preparation for upcoming clinical trials.
About Cellipont
Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapies. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve. To learn more, visit www.cellipont.com and follow us on LinkedIn.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company's lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company's initial focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit www.ernexatx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cellipont-bioservices-and-ernexa-therapeutics-enter-cell-therapy-manufacturing-partnership-to-advance-erna-101-toward-clinical-trials-in-ovarian-cancer-302597673.html
SOURCE Cellipont Bioservices
FAQ
What did Cellipont and Ernexa announce on Oct. 29, 2025 regarding ERNA-101 (ERNA)?
How will the Cellipont partnership affect ERNA-101 clinical readiness for ERNA?
Has ERNA-101 shown clinical results for ERNA Therapeutics (ERNA)?
Did Cellipont and Ernexa disclose financial terms or trial timelines for ERNA-101 (ERNA)?
What is the therapeutic approach of ERNA-101 by ERNA Therapeutics (ERNA)?
Why is an allogeneic iMSC approach important for ERNA's ERNA-101 program?
